April 2019 – Buhlmann Diagnostics Corp

Month: April 2019

Educational Webinar- Calprotectin in the Diagnosis of Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important
Continue Reading

Basophils Are Still Alive

Quality Assay & Sample Stability for Viable Basophils Basophil Activation Testing (often referred to as BAT) is a flow-cytometry-based functional assay that assesses the degree of cell activation after exposure to stimuli.3 Q: Do you know which BAT application makes sense for your lab? Are you thinking about implementing an allergy BAT?  Or are you
Continue Reading

BUHLMANN Quantum Blue® TDM Tutorial

View this demonstration of quantitative trough level measurement for TDM using the Quantum Blue® TDM rapid test technology.   Quantum Blue® Adalimumab:  Health Canada License: 101776 Quantum Blue® Infliximab: Health Canada License: 98838 US: (The Quantum Blue® tests are for Research Use Only. Not for use in diagnostic procedures.) Contact BUHLMANN Today! Contact us &
Continue Reading

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients

BÜHLMANN fCAL® ELISA Citation Foster, A. et al. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients. World J Gastroenterol. PMID: 30886509 DOI: 10.3748/wjg.v25.i10.1266. Highlight from this Publication ..."Notably, in keeping with adult IBD practice, our study shows that children should also have FC levels checked every 3 mo to ensure adequate monitoring."… Read Citation BÜHLMANN
Continue Reading